Magnesium chloride 0.16% (magnesium 8mmol/1litre) / Sodium chloride 0.9% infusion 1litre bags
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Magnesium chloride + Sodium chloride
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Magnesium chloride + Sodium chloride on the MHRA register
Magnesium chloride 0.16% (magnesium 8mmol/1litre) / Sodium chloride 0.9% infusion 1litre bags
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Neonatal parenteral nutrition (NG154)
Hypertension in adults: diagnosis and management (NG136)
The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 2 · 1970–2026
Showing the 50 most relevant studies, sorted by most relevant.
Brian H. Rowe, Jennifer A. Bretzlaff, Chris Bourdon, et al.
Annals of Emergency Medicine, 2000
Patil S, Falkowski A, Venkataiah VS, et al.
2026
- Temporomandibular Joint Disorders
- Muscle Cramp
- Electrolytes
BackgroundTemporomandibular disorders (TMDs) are a major cause of chronic orofacial pain, with myalgia of the masticatory muscles being central to symptom burden. Electrolyte modulation, particularly magnesium, may influence neuromuscular excitability and nociceptor sensitization, but no systematic review has synthesized the evidence for muscle pain syndromes or its relevance to TMD.ObjectivesTo evaluate the efficacy of electrolyte supplementation (magnesium, sodium, calcium, and potassium) in reducing muscle cramps and myalgia, and to explore the biological plausibility and potential extrapolation to TMD-related myofascial pain.MethodsThis systematic review followed PRISMA guidelines and was prospectively registered in PROSPERO (CRD420251120631). PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched from January 1995 to August 2025. Randomized or quasi-randomized trials of electrolyte supplementation for cramps or myalgia were eligible. Data extraction and risk-of-bias assessment (RoB 2 tool) were performed independently by 2 reviewers. Meta-analyses used random-effects models in R (v4.4.3) and Python (v3.11).ResultsThirteen trials were included. Magnesium was most frequently studied (10 RCTs). In pregnancy-associated cramps (4 trials, N≈364), magnesium significantly reduced cramp frequency compared with placebo (pooled RR 1.35, 95% CI: 1.05-1.74, P = .02). In nocturnal or persistent leg cramps in adults (4 trials, N≈396), no significant effect was found (MD -0.42 cramps/week, 95% CI: -1.15 to 0.31, P = .26). Intravenous magnesium showed no benefit in older adults, but a perioperative trial demonstrated reduced fasciculations and postoperative myalgia. Sodium-based solutions reduced cramp susceptibility in exercise and cirrhosis, while calcium and potassium lacked supportive evidence. Risk of bias was generally low to moderate.ConclusionMagnesium supplementation benefits pregnancy-related cramps but shows inconsistent effects in other populations. Sodium-based interventions are context-specific, and calcium and potassium remain unsupported. Magnesium is the most plausible candidate for translation to TMD myalgia, warranting targeted clinical trials.
Abstract licence: CC BY-NC-ND
Jia-Run Li, Quantong Jiang, Hu-Yuan Sun, et al.
Corrosion Science, 2016
K. de Weerdt, B. Lothenbach, M. Geiker
Cement and Concrete Research, 2019
G. Mohan, Mahesh B. Venkataraman, Judith C. Gomez-Vidal, et al.
Energy Conversion and Management, 2018
Carrió N, Garawani BE, Alahmad A, et al.
2026
- Burning Mouth Syndrome
- Calcium
- Magnesium
G. Song, A. Atrens, Xian Wu, et al.
Corrosion Science, 1998
A. M. Kirkendall, W. Connor, F. Abboud, et al.
The Journal of laboratory and clinical medicine, 1976
Geraint Williams, H. McMurray
Journal of The Electrochemical Society, 2008
L. Seigler, W.-T. Wu
Clinical chemistry, 1981
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.